Pfizer and BioNtech request European Medicines Agency to authorize vaccine for adolescents


Pfizer and BioNtech have requested the European Medicine Agency (EMA) to allow vaccination of children between the ages of 12 and 15 to increase the scope of vaccination.

New Delhi. With the rapid increase in the world, cases of corona infection are still increasing. However, on the other hand, vaccination campaign is also being carried out at a rapid pace to deal with this epidemic. In the same sequence, now Corona vaccine producers Pfizer and BioNtech have requested the European Medicine Agency (EMA) to authorize vaccines for adolescents as well.

The EMA said that vaccines should be allowed for children aged between twelve and fifteen years. In a joint statement, the two companies said they had requested EMA to authorize vaccines for teenagers between the ages of 12 and 15 as well.

Also read: – After Pfizer, now an alert has also been issued regarding Moderna, this side effect is also happening from this vaccine.

‘Pfizer and BioNotech announced today that they have requested the European Union (EMA)’ s Conditional Marketing Authority (CMA) in the European Union (EMA) for the use of the Pfizer-BioNotech vaccine for teens between the ages of 12 and 15 years.

Vaccine is 100 percent effective in children

The company has said that if approved by EMA, this rule will be valid in 27 countries of Europe. The company has previously made these requests to the US Food and Drug Administration (FDA) for the Emergency Use Authority (EUA) and plans to request additional amendments with regulatory authorities in the rest of the world.

According to the statement issued by the company, this decision has been taken after clinical trials on 12–15-year-old children. Health Minister Stephen Donley has said that he hopes we will be able to get vaccinated in July.

Also read: – Pfizer takes big step to investigate Corona Vaccine against new virus strains

According to the information, the decision is based on data from 3 clinical trials. The trial included 2,260 participants aged between 12 and 15 years. Results announced on March 31, 2021 found that the vaccine was 100 percent effective in participants with SARS-CoV-2 infection and strong antibody responses. According to the statement, after applying the second dose of the vaccine, it will remain in effect for the next two years.


Source link

Leave a Reply